Does Lactobacillus Exert a Protective Effect on the Development of Cervical and Endometrial Cancer in Women?

K Frąszczak, B Barczyński, A Kondracka - Cancers, 2022 - mdpi.com
Simple Summary Cervical cancer is the fourth most common cancer in women worldwide.
Tumour-related deaths are most frequent in low-and middle-income countries. Currently …

Probiotic-based vaccines may provide effective protection against COVID-19 acute respiratory disease

S Taghinezhad-S, AH Mohseni… - Vaccines, 2021 - mdpi.com
Severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2) infection, the
causative agent of COVID-19, now represents the sixth Public Health Emergency of …

Twenty years of research on HPV vaccines based on genetically modified lactic acid bacteria: an overview on the gut-vagina axis

S Taghinezhad-S, H Keyvani… - Cellular and Molecular …, 2021 - Springer
Most cervical cancer (CxCa) are related to persistent infection with high-risk human
papillomavirus (HR-HPV) in the cervical mucosa, suggesting that an induction of mucosal …

The First Clinical Use of a Recombinant Lactococcus lactis Expressing Human Papillomavirus Type 16 E7 Oncogene Oral Vaccine: A Phase I Safety and …

AH Mohseni, S Taghinezhad-S, H Keyvani - Molecular Cancer Therapeutics, 2020 - AACR
A dose-escalation, randomized, double-blind, placebo-controlled phase I clinical trial was
performed in healthy Iranian volunteer women to assess the safety, tolerability, and …

Oral immunization with recombinant Lactococcus lactis NZ9000 expressing human papillomavirus type 16 E7 antigen and evaluation of its immune effects in female …

AH Mohseni, V Razavilar, H Keyvani… - Journal of medical …, 2019 - Wiley Online Library
The ORFs of both native and codon‐optimized E7 genes were successfully fused to
SPusp45 signal peptide and expressed by a nisin‐controlled gene expression system in the …

Phase 1 safety and immunogenicity trial of recombinant lactococcus lactis expressing human papillomavirus type 16 E6 oncoprotein vaccine

S Taghinezhad-S, AH Mohseni, H Keyvani… - … Therapy Methods & …, 2019 - cell.com
The present study purposed to investigate the safety, tolerability, and immunogenicity of the
therapeutic NZ8123-HPV16-optiE6 vaccine, following oral vaccination. The safety and …

Protection against human papillomavirus type 16-induced tumors in C57BL/6 mice by mucosal vaccination with Lactococcus lactis NZ9000 expressing E6 oncoprotein

S Taghinezhad-S, AH Mohseni, H Keyvani… - Microbial …, 2019 - Elsevier
Recombinant strains of Lactococcus lactis NZ9000 that express native and codon-optimized
E6 protein (fused to the SPusp45 secretion signal) were successfully constructed by using …

Strain-specific differences in purification and VLP formation for a quadrivalent recombinant HPV vaccine

K Aghajani, A Asadollahi, T Taghizadeh… - Biochemical …, 2024 - Elsevier
Human papillomavirus (HPV) is responsible for causing various types of cancers, including
cervical cancer. Recombinant HPV vaccines are developed using recombinant DNA …

Plasmid Replicons for the Production of Pharmaceutical-Grade pDNA, Proteins and Antigens by Lactococcus lactis Cell Factories

SOD Duarte, GA Monteiro - International Journal of Molecular Sciences, 2021 - mdpi.com
The Lactococcus lactis bacterium found in different natural environments is traditionally
associated with the fermented food industry. But recently, its applications have been …

Efficient production and optimization of E7 oncoprotein from Iranian human papillomavirus type 16 in Lactococcus lactis using nisin-controlled gene expression (NICE) …

AH Mohseni, V Razavilar, H Keyvani, MR Razavi… - Microbial …, 2017 - Elsevier
The present work was aimed at investigating the expression and optimization of a human
papillomavirus (HPV) type 16 gene encoding oncoprotein E7 in Lactococcus lactis. We …